Schrodinger reports FY24 EPS ($2.57) , two estimates ($2.59)

Reports Q4 revenue $88.3M, consensus $83.2M. “We are delighted with Schrodinger’s (SDGR) excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing industry cycles and the impact of large contract renewals. Our drug discovery collaboration portfolio is expanding, driven by our new agreement with Novartis and expanded collaborations with Otsuka and Lilly, and we expect to report initial clinical data from our three lead proprietary programs this year,” said Ramy Farid, Ph.D., chief executive officer of Schrodinger. “We continue to see increasing momentum and conviction around our validated computational methods and are committed to remaining scientific leaders in this area. With our platform, our collaborations, our programs, and our strong financial position, we believe we are well positioned to deliver across all facets of our business in 2025 and beyond.”